For Immediate Release
October 16, 2003
For more information, contact:
Laura Kalies at email@example.com
iSBTc TO HOLD CONFERENCE PRIMER:
TUMOR IMMUNOLOGY AND BIOLOGICAL THERAPY
(Milwaukee)-The International Society for Biological Therapy of Cancer (iSBTc) will hold an educational Primer on Tumor Immunology and Biological Therapy of Cancer immediately before its Annual Meeting on October 30, 2003.
“This unique educational program will provide a fundamental understanding of tumor biology, immunology and molecular biology that are leading to new product development. This program has been designed specifically for health care professionals, industry scientists, graduate students and fellows” according to co-chairs Robert Dillman, MD and Elizabeth Repasky, PhD.
A series of basic science and clinical presentations will provide a state-of-the-art review of biological products that are FDA approved for cancer therapy, an introduction to clinical trials, and an overview of the current scientific paradigms in the fields of tumor biology, immunology, and molecular biology that are leading to new product development. Attendees will come away with a foundation that will facilitate critical assessment of presentations in the iSBTc Annual Meeting which follows the Primer.
Program faculty includes Mark W. Dewhirst, PhD, DVM (Duke University Medical Center), Robert O. Dillman, MD (Hoag Cancer Center), Crystall L. Mackall, MD (National Cancer Institute), Antoine Menoret, PhD (University of Connecticut Health Center),Julie R. Ostberg, PhD (Roswell Park Cancer Institute), Elizabeth A. Repasky, PhD (Roswell Park Cancer Institute), Paul Sondel, MD, PhD (University of Wisconsin), Antoine Menoret, PhD (University of Connecticut Health Center), and Jon M. Wigginton, MD (National Cancer Institute).
About the iSBTc
The Society for Biological Therapy was founded in 1984 with 40 charter members. The Society currently has over 450 members consisting primarily of MDs, PhDs, RNs, and corporate representatives. The purpose and mission of the International Society for Biological Therapy of Cancer (iSBTc) is to bring together those individuals actively involved in the preclinical and clinical investigation of biological agents in the treatment of cancer. Scientific and business meetings have been held annually since the first Annual Meeting of SBT in 1986. At the 2002 business meeting held November 9, 2002, the SBT membership voted to officially change the name of the Society and it thus became the International Society for Biological Therapy of Cancer (iSBTc).